CN114159573B - A pharmaceutical composition for treating viral hepatitis - Google Patents
A pharmaceutical composition for treating viral hepatitis Download PDFInfo
- Publication number
- CN114159573B CN114159573B CN202210101742.8A CN202210101742A CN114159573B CN 114159573 B CN114159573 B CN 114159573B CN 202210101742 A CN202210101742 A CN 202210101742A CN 114159573 B CN114159573 B CN 114159573B
- Authority
- CN
- China
- Prior art keywords
- hepatitis
- pharmaceutical composition
- hbsag
- hbeag
- hbv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Abstract
The application provides a pharmaceutical composition for treating viral hepatitis, which comprises a proton pump inhibitor and a non-steroidal anti-inflammatory drug, and application thereof in treating or preventing the viral hepatitis and application thereof in preparing drugs for treating or preventing the viral hepatitis, particularly hepatitis B.
Description
Technical Field
The application relates to the technical field of antiviral drugs, in particular to a compound for treating or preventing viral hepatitis, a pharmaceutical composition and application thereof.
Background
Human Hepatitis B Virus (HBV) infection is a major public health problem worldwide. After acute hepatitis B virus infection, about 8% of hepatitis B virus still develops into chronic hepatitis B infection, and persistent HBV infection can cause cirrhosis and even liver cancer. The hepatitis B transmission pathway is mainly through vertical transmission and horizontal transmission. Vertical transmission refers to mother-to-baby transmission; horizontal transmission is primarily through the blood.
The treatment of hepatitis b is also a long-term process, and the treatment aims to inhibit or eliminate HBV to the maximum extent, relieve inflammation and necrosis of liver cells and liver fibrosis, delay and stop the progress of diseases, and reduce and prevent the occurrence of liver decompensation, liver cirrhosis, HCC and complications thereof, thereby improving the quality of life and prolonging the survival time.
There are many hepatitis b therapeutic drugs on the market today, mainly by antiviral treatment with interferon or nucleoside analogues. In the case of interferon, recombinant DNA leukocyte interferon (IFN-. Alpha.) inhibits the replication of HBV. However, when the interferon is used for treating hepatitis B, strong adverse reactions are often accompanied, including bone marrow suppression, thyroid function influence, depression and the like.
Nucleoside analogues inhibit HBV production primarily by inhibiting reverse transcriptase activity during HBV replication, and clinically useful drugs include the following classes: lamivudine and famciclovir, such as acyclovir, adefovir, entecavir, tenofovir, foscarnet and the like, and the medicaments have certain HBV inhibiting effect.
Although these reverse transcriptase inhibitors can effectively reduce HBV DNA level and make patients control HBV level, they have no direct effect on the clearance of HBeAg and HBsAg because their target of action is the process of reverse transcription of RNA into DNA. Therefore, the serological transformation probability of HBeAg and HBsAg in the single-drug treatment of the nucleoside analogue is very low, hepatitis B cannot be really cured, and patients need to take the drug for a long time or even for life.
Although the reverse transcriptase inhibitor can control the level of hepatitis B virus, the problems of drug resistance, huge medical cost, serious side effects of the drug and the like are not small. The key point is that at present, no medicine can completely eliminate viruses to achieve the functional cure of hepatitis B. Therefore, there is an urgent need in the art to provide a new drug for treating hepatitis b that achieves a functional cure without the need for long-term or even lifelong administration.
Lansoprazole (Lansoprazole) Lansoprazole is a novel drug for inhibiting gastric acid secretion, has obvious inhibition effect on basic gastric acid secretion and gastric acid secretion caused by all irritants (such as histamine, carbamoylcholine and the like), has the acid inhibition effect obviously superior to that of an H2 receptor blocker, and has obvious dependency relationship between the inhibition degree and the concentration. Lansoprazole can rapidly penetrate a parietal cell membrane to be converted into sulfenic acid and sulfenic derivatives under an acidic condition to exert drug effect, has an inhibition effect on helicobacter pylori (Hp), and is 4 times that of omeprazole. The traditional Chinese medicine composition is clinically used for treating duodenal ulcer, gastric ulcer, anastomotic oral ulcer, reflux esophagitis and Zong-ai syndrome, and has a remarkable curative effect.
Non-steroidal anti-inflammatory Drugs (NSAIDs) are anti-inflammatory Drugs without steroidal structures, NSAIDs are first synthesized from aspirin in 1898, and hundreds of over 100 years are on the market, and the Drugs comprise aspirin, acetaminophen, indomethacin, naproxen, diclofenac, ibuprofen, nimesulide, rofecoxib, celecoxib and the like, have the effects of anti-inflammation, antirheumatic, pain relieving, antipyretic, anticoagulation and the like, and are widely used for clinically relieving osteoarthritis, rheumatoid arthritis, various fever and various pain symptoms.
Disclosure of Invention
The present application provides a pharmaceutical composition comprising a proton pump inhibitor, and a non-steroidal anti-inflammatory drug, and its use for the preparation of a medicament for the treatment or prevention of viral hepatitis, in particular for reducing HBsAg and/or HBeAg levels.
The inventors have surprisingly found that the combination of a proton pump inhibitor and a non-steroidal anti-inflammatory drug is able to produce a synergistic effect, in particular in reducing the level of HBsAg and/or HBeAg, which is stronger than either one and better than the additive effect of the two. The composition of the application hopefully achieves the effect of eliminating hepatitis B virus and even achieves complete cure.
In one embodiment, the proton pump inhibitor comprises at least one of omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and the non-steroidal anti-inflammatory agent comprises at least one of aspirin, acetaminophen, indomethacin, naproxen, naproxone, diclofenac, ibuprofen, nimesulide, rofecoxib, and celecoxib.
In one embodiment, the pharmaceutical composition is administered by a route selected from the group consisting of: oral, rectal, nasal, pulmonary, topical, buccal and sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural.
In one embodiment, the pharmaceutical composition is administered orally, preferably in the form of a tablet or capsule.
The application also provides application of the pharmaceutical composition in preparing a medicament for treating viral hepatitis.
The application also provides application of the lansoprazole or a pharmaceutically acceptable salt thereof and the celecoxib or the pharmaceutically acceptable salt thereof in preparing a medicament for reducing the level of HBV DNA, HBsAg and/or HBeAg.
In one embodiment, the viral hepatitis is hepatitis b or hepatitis d, and the use is preferably the use of reducing the level of HBsAg and/or HBeAg in a hepatitis b patient.
The technical scheme of this application has following beneficial effect:
1. the use of a combination of a proton pump inhibitor and a non-steroidal anti-inflammatory drug, particularly lansoprazole and celecoxib, in the treatment or prevention of viral hepatitis provides a novel viral hepatitis treatment option.
2. The composition of lansoprazole and celecoxib has a synergistic effect on effectively reducing the level of HBsAg and/or HBeAg of hepatitis B virus, and is expected to become a subsequent pharmaceutical composition for functional cure of hepatitis B.
3. As a common proton pump inhibitor and a non-steroidal anti-inflammatory drug in the market, the compound has excellent clinical safety and pharmacokinetic property and better druggability.
4. The composition of the proton pump inhibitor and the non-steroidal anti-inflammatory drug can obviously improve the effect of eliminating hepatitis B virus and has better synergy.
Description of the drawings:
FIG. 1: HD017, HD017 and HD042 combined the inhibition results for HBeAg.
FIG. 2: HD017, HD017 and HD042 combined the result of inhibition of HBsAg.
FIG. 3: the inhibition synergy of the combination of HD017 and HD042 on HBeAg was analyzed.
FIG. 4 is a schematic view of: HD017 and HD042 combination was analyzed for the inhibitory synergy of HBsAg.
Detailed Description
The inventor screens out the composition with the hepatitis B treatment effect through multiple experiments, and further verifies through biological experiments that the composition has the effect of potentially removing HBsAg and/or HBeAg, is expected to functionally cure hepatitis B and remove hepatitis B virus.
In one aspect, the present application provides a pharmaceutical composition comprising a proton pump inhibitor and a non-steroidal anti-inflammatory drug, in particular for reducing HBsAg and/or HBeAg levels.
In one embodiment, the proton pump inhibitor comprises at least one of omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole, and the non-steroidal anti-inflammatory agent comprises at least one of aspirin, acetaminophen, indomethacin, naproxen, naproxone, diclofenac, ibuprofen, nimesulide, rofecoxib, and celecoxib.
In one embodiment, the pharmaceutical composition is administered by a route selected from the group consisting of: oral, rectal, nasal, pulmonary, topical, buccal and sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural.
In one embodiment, the pharmaceutical composition is administered orally, for example in the form of a tablet or capsule.
The application also provides application of the pharmaceutical composition in preparing a medicament for treating viral hepatitis.
In one embodiment, the viral hepatitis is hepatitis b or hepatitis d, and the use is the use of reducing the level of HBsAg and/or HBeAg in a hepatitis b patient.
Definition of terms
Lansoprazole is a novel drug for inhibiting gastric acid secretion, has obvious inhibition effect on basic gastric acid secretion and gastric acid secretion caused by all stimulators (such as histamine, carbamoylcholine and the like), has the inhibition effect obviously superior to that of an H2 receptor blocker, and has obvious dependence on the inhibition degree and concentration. Lansoprazole can rapidly pass through parietal cell membrane under acidic condition and is converted into sulfenic acid and sulfenic derivatives to exert drug effect, and has inhibitory effect on helicobacter pylori (Hp) 4 times that of omeprazole. The traditional Chinese medicine composition is clinically used for treating duodenal ulcer, gastric ulcer, anastomotic oral ulcer, reflux esophagitis and Zollinger-Ellison syndrome, and has obvious curative effect.
Non-steroidal anti-inflammatory Drugs (NSAIDs) are anti-inflammatory Drugs without steroidal structures, NSAIDs are first synthesized from aspirin in 1898, and hundreds of over 100 years are on the market, and the Drugs comprise aspirin, acetaminophen, indomethacin, naproxen, diclofenac, ibuprofen, nimesulide, rofecoxib, celecoxib and the like, have the effects of anti-inflammation, antirheumatic, pain relieving, antipyretic, anticoagulation and the like, and are widely used for clinically relieving osteoarthritis, rheumatoid arthritis, various fever and various pain symptoms.
Lansoprazole and rofecoxib of the present application include deuterated species thereof.
Viral hepatitis
The etiological typing of viral hepatitis is currently recognized by five hepatitis viruses, namely hepatitis A virus, hepatitis B virus, hepatitis C virus, hepatitis D virus and hepatitis E virus, which are respectively written as HAV, HBV, HCV, HDV and HEV, and the rest are RNA viruses except the hepatitis B virus which is a DNA virus.
Hepatitis b is an infectious disease mainly caused by hepatitis b virus, and is a liver disease. Clinically, the symptoms of anorexia, nausea, epigastric discomfort, liver pain and hypodynamia are mainly manifested. Some patients may have jaundice fever and hepatomegaly with impaired liver function. Some patients can become chronic, even develop cirrhosis of the liver, and a few can develop liver cancer.
The etiological agent of hepatitis b is hepatitis b virus, abbreviated as HBV, and hepatitis b virus is DNA virus. The genome is a double-stranded, circular, incompletely closed DNA. The outermost layer of the virus is the outer membrane or coat membrane of the virus, the inner layer is the core, and the nucleoprotein is the core antigen (HBcAg) and cannot be detected in serum. Serum from HBsAg positive patients was observed under electron microscope to show 3 kinds of particles, circular and filamentous particles with a diameter of 22nm, and less spherical particles with a diameter of 42 angstroms, also called Dane's particles, as complete HBV particles.
The markers for hepatitis b were detected as follows: (1) HBsAg and anti-HBs: HBsAg positive indicates that HBV is currently in the stage of infection, and anti-HBs positive for immunoprotective antibodies indicates that immunity to HBV has developed. The diagnosis basis of the chronic HBsAg carrier is that the chronic HBsAg carrier has no clinical symptoms and physical signs, the liver function is normal, and the HBsAg is continuously positive for more than 6 months. (2) HBeAg and anti-HBe: HBeAg positive is an index of HBV active replication and strong infectivity, and the change of the detected serum from HBeAg positive to anti-HBe positive indicates that the disease has remission and weakened infectivity. (3) HBcAg vs anti-HBc: HBcAg positive suggests that there is a direct reaction of complete HBV particles, and active replication of HBV is less clinically useful due to the complex detection method. anti-HBc is a marker of HBV infection, and anti-HBc IgM positive indicates that the virus is replicated in vivo at an early stage of infection. HBsAg, HBeAg and anti-HBc are all positive in chronic mild hepatitis B and HBsAg carriers, and have high infectivity index and are difficult to convert from negative to positive.
As used herein, "therapeutically effective amount" or "effective amount" refers to an amount that is effective at dosage and for a period of time required to achieve the desired therapeutic result. A therapeutically effective amount of a therapeutic agent for hepatitis b will depend on the nature of the disorder or condition and on the particular agent, and can be determined by standard clinical techniques known to those skilled in the art.
The therapeutic result may be, for example, alleviation of symptoms, prolongation of survival, increased mobility, and the like. The therapeutic result need not be a "cure". The therapeutic outcome may also be prophylactic.
Route of administration
The medicaments or pharmaceutical compositions of the present disclosure are administered by any route suitable for the condition to be treated. Suitable routes include oral, rectal, nasal, pulmonary, topical (including buccal and sublingual), vaginal and parenteral (including subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural) and the like. In certain embodiments, the medicament or pharmaceutical composition disclosed herein is administered by intravenous injection. It will be appreciated that the preferred route may vary depending on, for example, the condition of the recipient. One advantage of the disclosed medicaments or pharmaceutical compositions is that they are orally bioavailable and can be administered orally.
In a preferred embodiment, the composition is administered by a route selected from the group consisting of: oral, rectal, nasal, pulmonary, topical, buccal and sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural.
In a preferred embodiment, the composition is formulated for oral administration, preferably in the form of a tablet or capsule.
The pharmaceutical compositions of the present disclosure may be formulated with conventional carriers and excipients, which will be selected in accordance with common practice. Tablets will contain excipients, glidants, fillers, binders and the like. Aqueous formulations are prepared in sterile form and, when used for delivery by non-oral administration, are generally isotonic. All formulations will optionally contain Excipients such as those described in the Handbook of Pharmaceutical Excipients (1986).
The formulations include those suitable for the aforementioned routes of administration. The compositions of the present application may be in the form of a unit dosage form of two or more drugs, or the drugs may be combined together to form a unit dosage form. The formulations or dosage forms may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations are commonly found in Remington's Pharmaceutical Sciences (Mack Publishing co., easton, PA). Such methods include the step of bringing into association the active ingredient with the carrier which is composed of one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid carriers or finely divided solid carriers or both, and then shaping the product as necessary.
Formulations of the present application suitable for oral administration may exist as follows: discrete units, such as capsules or tablets, each containing a predetermined amount of active ingredient; a powder or granules; solutions or suspensions in aqueous or non-aqueous liquids; or an oil-in-water liquid emulsion or a water-in-oil liquid emulsion. The pharmaceutical compositions of the present disclosure may also be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. The composition may also be in a sustained or controlled release dosage form.
Objects, advantages and novel features of the present application will become apparent to one of ordinary skill in the art from the following description of the embodiments.
Examples
Application of HepG2-NTCP cells to evaluation of in-vitro anti-HBV synergistic effect of lansoprazole and celecoxib
1. Compound (I)
Celecoxib (No. HD 042) and lansoprazole (No. HD 017) were purchased from shanghai Tao Su biotechnology limited.
The compound preparation method comprises the following steps:
in the case of preparation of 20mM concentration, volume (. Mu.l) = sample mass (. Mu.l). Times.purity ÷ molecular weight ÷ 20X 10 of DMSO as solvent 6
The control compound was entecavir (ETV, lot: P1214012;99.0% purity) purchased from Shanghai Tantaceae technology, inc. The mother liquors of the above compounds were all at 20mM concentration and stored at-20 ℃.
2. Cells and culture media
HepG2-NTCP cells: provided by Shanghai Mingkude New drug development Co., ltd
Freezing and storing a PHH culture medium: mainly a DMEM medium (Gibco cat # 11960051) containing 10% fetal bovine serum (FBS, hyclon cat # SV 3008703) and 1% penicillin-streptomycin, mainly used for cell culture.
Freezing and storing PHH plating culture medium: mainly containing 10% fetal bovine serum (FBS, hyclon cat # SV 3008703) and 1% penicillin-streptomycin InvitroGRO CP Medium (BIOIVT cat # S03316), and is mainly used for cell plating.
Virus infection medium: mainly contains 1% penicillin-streptomycin Williams' Medium E (SIGMA goods number W1878), and is mainly used for HBV virus infection.
3. Primary reagent
The main other reagents and cells used are shown in table 1.
TABLE 1 Primary reagents and cells
4. Experimental protocol
Plating cells and compound treatment
Infectious virus and compound treatment
On day 2, cells were pretreated with the compound for 2 hours before the addition of D-type HBV to infect HepG2-NTCP cells (compound was added at the same time as infection). The concentrations of the test compounds are shown in Table 2, and combinations of two compounds are provided.
The culture medium containing the compound was replaced once on days 3, 5 and 7. On day 9, cell supernatants were collected for detection of HBV DNA (qPCR), HBeAg and HBsAg (ELISA). After collecting the cell supernatant, cellTiter-Glo was added to test cell viability, and the collected cells were stored frozen (for future use).
TABLE 2 test concentrations of the respective Compounds
Sample detection
1) qPCR method for detecting HBV DNA content in cell culture supernatant
DNA was extracted from the cell culture supernatant according to the QIAamp 96DNA Blood Kit instructions. The content of HBV DNA was detected by qPCR method. And (3) PCR reaction: at 95 ℃ for 10min;95 ℃ for 15sec; at 60 ℃ for 1min,40 cycles.
2) ELISA method for detecting content of HBeAg and HBsAg in cell culture supernatant
The method refers to the kit specification, and the method is briefly described as follows: respectively adding 50 mu l of standard substance, sample and reference substance into a detection plate, then adding 50 mu l of enzyme conjugate into each hole, incubating for 60 minutes at 37 ℃, washing the plate with washing liquor, then sucking dry, then adding 50 mu l of premixed luminescent substrate, incubating for 10 minutes at room temperature in a dark place, and finally measuring the luminescent value by an enzyme-linked immunosorbent assay.
CellTiter-Glo cell viability assay
Cell viability was determined with reference to CellTiter-Glo kit instructions, the method is briefly as follows: after collecting the cell culture supernatant, cellTiter-Glo (medium 1:1 dilution) was added to each well, incubated at room temperature for 10 minutes, and the luminescence was measured by a microplate reader.
Data analysis
HBV DNA inhibition (%) = (1-HBV copy number of compound group sample/HBV copy number of DMSO control group) × 100%
HBsAg inhibition (%) = (1-HBsAg value of sample/DMSO control HBsAg value) × 100%
HBeAg inhibition (%) = (1-HBeAg value of sample/DMSO control HBeAg value) × 100%
% cell viability = (signal value of sample-signal value of media control)/(signal value of DMSO control-signal value of media control) × 100%
EC50 values were calculated using GraphPad Prism software (four parameter logistic equations).
Combination Index (CI) software CompuSyn software V1.0 software was used to analyze the synergy of celecoxib and lansoprazole using the Non-Constant Combo method.
Index of experimental acceptance
Other data in an experiment are considered valid if the control compound tested in the experiment gave the expected result. And the data will be analyzed and accounted for in the report.
Analysis of results
The detection results are shown in table 3, table 4, table 5 and figures 1-4, and the combination of celecoxib and lansoprazole has obvious synergistic effect on inhibiting HBsAg and HBeAg.
To analyze their synergy more clearly, a series of data were analyzed using the Combination Index (CI) software CompuSyn software V1.0. Software, see tables 3 and 4 for results.
The results of the control compound ETV are shown in table 5.
TABLE 3 inhibition rates of HD017 and HD042 against HBeAg and HBsAg, respectively
TABLE 4 HD017 HD042 combined effect on HBeAg inhibition rate
TABLE 5 combined effect analysis of HBsAg inhibition rate by HD017+HD042
The test results show that when HD017 and HD042 are used together, HBsAg and HBeAg can be effectively reduced, and obvious synergistic effect is achieved.
According to the results, the combination of the celecoxib and the lansoprazole can generate a synergistic effect, and is expected to become a novel drug combination for treating hepatitis B.
While the present application has been described with reference to particular embodiments, those skilled in the art will recognize that changes or modifications can be made to the described embodiments without departing from the spirit and scope of the present application, which is defined by the appended claims.
Claims (6)
1. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment or prevention of hepatitis b, wherein the pharmaceutical composition comprises lansoprazole, or a pharmaceutically acceptable salt thereof, and celecoxib, or a pharmaceutically acceptable salt thereof.
2. The use of claim 1, wherein the pharmaceutical composition is a pharmaceutical composition administered by a route selected from the group consisting of: oral, rectal, nasal, pulmonary, topical, buccal and sublingual, vaginal, parenteral, subcutaneous, intramuscular, intravenous, intradermal, intrathecal and epidural.
3. The use of claim 2, wherein the pharmaceutical composition is an oral dosage form.
4. The use of claim 3, wherein the pharmaceutical composition is a tablet or capsule.
5. Use of lansoprazole, or a pharmaceutically acceptable salt thereof, and celecoxib, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing hepatitis b or reducing the level of HBsAg and/or HBeAg.
6. The use of any one of claims 1-5, wherein the use is to reduce the level of HBsAg and/or HBeAg in a hepatitis B patient.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210101742.8A CN114159573B (en) | 2022-01-27 | 2022-01-27 | A pharmaceutical composition for treating viral hepatitis |
| PCT/CN2022/094169 WO2023142317A1 (en) | 2022-01-27 | 2022-05-20 | Pharmaceutical composition for treating viral hepatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210101742.8A CN114159573B (en) | 2022-01-27 | 2022-01-27 | A pharmaceutical composition for treating viral hepatitis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114159573A CN114159573A (en) | 2022-03-11 |
| CN114159573B true CN114159573B (en) | 2023-01-24 |
Family
ID=80489547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210101742.8A Active CN114159573B (en) | 2022-01-27 | 2022-01-27 | A pharmaceutical composition for treating viral hepatitis |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114159573B (en) |
| WO (1) | WO2023142317A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114159573B (en) * | 2022-01-27 | 2023-01-24 | 中以海德人工智能药物研发股份有限公司 | A pharmaceutical composition for treating viral hepatitis |
| CN114159572B (en) * | 2022-01-27 | 2023-01-24 | 中以海德人工智能药物研发股份有限公司 | A pharmaceutical composition for the treatment of viral hepatitis |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112933085A (en) * | 2020-12-28 | 2021-06-11 | 中以海德人工智能药物研发股份有限公司 | Application of compound in preparation of medicine for treating or preventing viral hepatitis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005213472A1 (en) * | 2004-02-10 | 2005-08-25 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory agent |
| CN102294031B (en) * | 2011-09-07 | 2013-02-20 | 沈阳亿灵医药科技有限公司 | Pharmaceutical formulation comprising proton pump inhibitor, NSAID and antacids |
| EP2755641A4 (en) * | 2011-09-14 | 2015-03-18 | Pozen Inc | Controlled dosing of clopidogrel with gastric acid inhibition therapies |
| JP2015145343A (en) * | 2014-01-31 | 2015-08-13 | 公立大学法人和歌山県立医科大学 | Novel pharmaceutical use of lansoprazole |
| RU2736481C2 (en) * | 2016-03-01 | 2020-11-17 | Эмерджинг Вайрал Терапьютикс (Хк) Лимитед | Compositions and methods for treating influenza virus |
| CN114159573B (en) * | 2022-01-27 | 2023-01-24 | 中以海德人工智能药物研发股份有限公司 | A pharmaceutical composition for treating viral hepatitis |
-
2022
- 2022-01-27 CN CN202210101742.8A patent/CN114159573B/en active Active
- 2022-05-20 WO PCT/CN2022/094169 patent/WO2023142317A1/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112933085A (en) * | 2020-12-28 | 2021-06-11 | 中以海德人工智能药物研发股份有限公司 | Application of compound in preparation of medicine for treating or preventing viral hepatitis |
Non-Patent Citations (1)
| Title |
|---|
| Tiziana Larussa等."Short-term Therapy with Celecoxib and Lansoprazole Modulates Th1⁄Th2 Immune Response in Human Gastric Mucosa".《Helicobacter》.2010,449-459. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114159573A (en) | 2022-03-11 |
| WO2023142317A1 (en) | 2023-08-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114159573B (en) | A pharmaceutical composition for treating viral hepatitis | |
| Caporali et al. | Safety of tumor necrosis factor α blockers in hepatitis B virus occult carriers (hepatitis B surface antigen negative/anti–hepatitis B core antigen positive) with rheumatic diseases | |
| CN114159572B (en) | A pharmaceutical composition for the treatment of viral hepatitis | |
| CN112933085B (en) | Application of compound in preparation of medicine for treating or preventing viral hepatitis | |
| CN114209844B (en) | A pharmaceutical composition for treating viral hepatitis | |
| CN115252664A (en) | Application of effective component of Geranium wilfordii for treating or preventing viral hepatitis | |
| CN109364074B (en) | Application of 6-aminonicotinamide as effective component in preparing medicament for treating hepatitis B | |
| CN114423423B (en) | Pharmaceutical composition for treating or preventing viral hepatitis and application thereof | |
| CN114515338B (en) | Pharmaceutical composition for treating viral hepatitis | |
| CN115105519A (en) | Pharmaceutical composition for treating hepatitis B and preparation method thereof | |
| CN115944629A (en) | Use of rapamycin for treating or preventing hepatitis B | |
| CN114259492A (en) | Application of nitazoxanide in treating hepatitis B | |
| WO2012058795A1 (en) | Uses of unsaturated fatty acids for inhibiting virus replication and /or infection | |
| CN115518072A (en) | A pharmaceutical composition for treating viral hepatitis | |
| CN114903891B (en) | Application of saquinavir in treatment or prevention of hepatitis B | |
| CN114224888B (en) | Application of lansoprazole in preparing medicine for treating or preventing viral hepatitis | |
| CN115671099A (en) | A pharmaceutical composition for treating viral hepatitis | |
| CN115607560A (en) | Pharmaceutical composition for treating hepatitis B and preparation method thereof | |
| CN115429789A (en) | Use of phenolic compounds for treating or preventing viral hepatitis | |
| CN116407638A (en) | Pharmaceutical composition for treating viral hepatitis | |
| KR20200022753A (en) | Use of ciclopirox to inhibit HBV core assembly | |
| CN113440507A (en) | Application of leonurine in preparation of anti-hepatitis B virus drugs | |
| WO2020040327A1 (en) | Use of ciclopirox for inhibiting hbv core assembly | |
| CN115252794A (en) | A composition for treating or preventing viral hepatitis | |
| CN115245569A (en) | A pharmaceutical composition for the treatment of viral hepatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |